Navigation Links
Litigation Predicted in Wake of FAA Ban of Chantix Use by Pilots and Air Traffic Controllers: Smoking Cessation Drug Target of Controversy
Date:5/22/2008

BIRMINGHAM, Ala., May 22 /PRNewswire/ -- A veteran pharmaceutical litigation attorney predicted today that pharmaceutical giant Pfizer will face lawsuits from individuals who claim to have been harmed by its popular smoking cessation drug Chantix. The FAA issued an immediate ban on the use of Chantix by pilots and air traffic controllers on May 21 after receiving an analysis of adverse events published by the Institute for Safe Medication. The report cites cases that allege Chantix may cause serious unintended side effects including loss of consciousness.

Kristian Rasmussen, a veteran pharmaceutical litigation attorney with the law firm Cory Watson Crowder & DeGaris said, "The magnitude of the health risks associated with Chantix is alarming - we are trying to determine whether the drug maker, Pfizer, failed to disclose information it may have had about adverse side effects." Rasmussen said his team, that includes pharmaceutical and medical experts along with attorneys, has been investigating reports of devastating side effects for more than year. "What we are finding is that the magnitude of the safety signal associated with using Chantix is alarming both in terms of severity of injury and the number of different serious reactions," said Rasmussen.

After requesting an accelerated review by the FDA, Chantix was approved for use in the U.S. in May, 2006. Chantix revenues hit $883 million in 2007, according to corporate performance reports available on the company's website. The Institute for Safe Medication report, cited in the FAA's ban on Chantix use among pilots and air traffic controllers, is the latest in a serious of reports highlighting concerns about the drug. In November, 2007, the U.S. Food and Drug Administration released a Preliminary Assessment specifically highlighting the number of reports noting an association between suicide and attempted suicide within days to weeks of initiating Chantix treatment.

On February 1, 2008, public health concerns intensified when the FDA issued a Public Health Advisory stating that "Serious neuropsychiatric symptoms have occurred in patients taking Chantix." Symptoms outlined include changes in behavior, agitation, depressed mood, suicidal ideation, and attempted and completed suicide. Rasmussen says more studies are likely as attorneys move forward with litigation.

About Cory Watson Crowder & DeGaris

Cory Watson Crowder & DeGaris is recognized nationally for its practice in mass torts litigation, multidistrict litigation and complex litigation including class actions, products liability, business and securities litigation, environmental litigation and mass torts litigation of defective medical devices and pharmaceuticals.


'/>"/>
SOURCE Cory Watson Crowder & DeGaris
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Warner Chilcott Announces Settlement of Securities Litigation
2. Seattle-Based Law Firm Williams Kastner Receives Significant Defense Verdict in Trade Secret Business Litigation Case
3. KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation
4. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
5. Peter Burg Appointed as Co-Chair of the Plaintiffs Steering Committee and the Executive Committee for the Gadolinium-Based Contrast Agents Product Liability Multi-District Litigation
6. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
7. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
8. Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
9. Information About The Airborne Health, Inc. Settlement, and Other Ongoing Litigation Alleging False and Deceptive Marketing Of Airborne(R)
10. Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation
11. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... ... Image One USA veteran franchise owner Maria Bogacki is bringing ... Nashville that will benefit. , “I’ve enjoyed being a part of the Image One ... question that I would bring my business with me,” Bogacki said. “The entire Image ...
(Date:2/11/2016)... ... February 11, 2016 , ... The ... among the top five firms in the “2015/2016 Best in KLAS: Software and ... Staffing. KLAS is a research and insights firm on a global mission to ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... ... and advocates will discuss how to improve care by making data on heart ... heart disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... Surgery, Dallas plastic surgeon , Dr. Rod J. Rohrich, and colleagues, examine ... Dr. Rohrich outlines recommendations for rhinoplasty surgeons when addressing this vital area. , ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical ... technology, with highly adaptable algorithms, has been updated to help Emergency Department physicians ... symptoms consistent with Zikas and a travel history to affected regions, or potential ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016 Potrero Medical, Inc., the developer of the ... appointment of George M. Rapier, III , MD, to ... , WellMed is one of the nation,s largest physician ... members in Texas and ... his own internal medicine practice, he has been instrumental to ...
(Date:2/11/2016)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... development services for the pharmaceutical and biotechnology industries, ... in its Charleston, SC ... recent investments. Charleston ... with small-scale lyophilization. The site has invested in ...
(Date:2/11/2016)... SEOUL, South Korea , Feb. 11, 2016 Wearable posture tracker, ALEX , has ... project fully funded and just seven days left to go, ALEX is said to be delivered to ... http://photos.prnewswire.com/prnh/20160211/332248 ... ... ...
Breaking Medicine Technology: